"HEAD-TO-HEAD COMPARISON:FLUTICASONE/FORMOTEROL VS BUDESONIDE/FORMOTEROL IN MILD–MODERATE ASTHMA"

Abstract

Introduction: The chronic inflammatory respiratory condition known as bronchial asthma affects millions of people all over the world and has an important impact on the quality of life of those affected. The most effective method for managing asthma is the combination of inhaled corticosteroids (ICSs) and long-acting beta-agonists (LABAs). However, there has been a relatively limited amount of research conducted on the safety and effectiveness of fluticasone and formoterol (FFF) and budesonide and formoterol (BFF) in patients who have mild to moderate asthma.
Aims and Objectives: The primary objective is to compare the improvement in “FEV1/FVC ratio” and health status among both groups. FEV1/FVC ratio and FEV1 values will be assessed using spirometry at baseline, weeks 2, 4 and 8 weeks. Secondary objective is to compare the adverse effects among both the groups Methodology: This institution-based, prospective, randomized, observational, open-labeled study was conducted at the Pulmonary Medicine Outpatients Department of “Sree Balaji Medical College and Hospital, Chennai”, over one year. Eighty adult patients were randomized into two groups: Group 1 (FFF) and Group 2 (BFF), receiving respective treatments twice daily. Spirometry were recorded at baseline, Weeks 2, 4, and 8. Adverse effects were also monitored.
Results: Both treatment groups showed significant improvement in lung function and symptom control. However, FFF demonstrated greater improvement in spirometry values at Weeks 2, 4, and 8 (p < 0.05). Additionally, the FFF group exhibited better tolerability, with fewer adverse effects reported at Weeks 2 and 4.
Conclusion: While both treatment regimens effectively managed asthma symptoms, the FFF combination exhibited superior efficacy and safety. It proved to be a more effective option for asthma management, ensuring better pulmonary function and symptom relief with fewer adverse effects.